Compounds and methods for preventing or treating upper respiratory virus infections in humans and animal species are disclosed. The compounds may exhibit antimicrobial, antiviral, anti-inflammatory, anticoagulant or cytoprotective activities. The methods may deliver compounds to be delivered to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections, such as influenza, SARS, and SARS-CoV-2. Therapeutic swabs comprising one or more compounds are may be used to deliver one or more compounds to deliver the above primary sites of the individuals infected with one or more upper respiratory viruses or other pathogens.

A breathing treatment delivery device is disclosed for providing atomized medicine or oxygen to a patient. The breathing treatment delivery device can include a supply device configured to dispense atomized medicine or oxygen through a dispensing end of the supply device. A cap can have a device side and a delivery side, the device side including an opening receiving and in fluid communication with the dispensing end of the supply device. A treat holder can be positioned on the delivery side of the cap. At least one aperture can be defined in the delivery side of the cap adjacent the treat holder, a pneumatic passage formed through the cap between the opening in the device side of the cap and the aperture. A patient can enjoy a piece of candy or other treat retained by the treat holder during treatment while breathing in the desired medicine or oxygen.

A method, device, and kit for providing fluid to a patient, the device includes a food-contact-safe sponge and a handle, the handle supporting the sponge.

Compounds and methods for preventing or treating upper respiratory virus infections in humans and animal species are disclosed. The compounds may exhibit antimicrobial, antiviral, anti-inflammatory, anticoagulant or cytoprotective activities. The methods may deliver compounds to be delivered to the nasal and oral cavities, nasopharynx, and posterior pharynx, the primary sites of upper respiratory infections, such as influenza, SARS, and SARS-CoV-2. Therapeutic swabs comprising one or more compounds are may be used to deliver one or more compounds to deliver the above primary sites of the individuals infected with one or more upper respiratory viruses or other pathogens.

The present invention relates generally to devices and methods for treating ear infections and clearing excess fluid from Eustachian tubes.

The present invention relates generally to devices and methods for treating ear infections and clearing excess fluid from Eustachian tubes.

The present invention includes compositions and methods for the treatment, softening and removal of ear wax by administering to the ear a solution of a semi-fluorinated alkane according to the formula: RFRH or RFRHRF, wherein RF is a perfluorinated hydrocarbon segment with 20 or less carbon atoms, and RH is a non-fluorinated hydrocarbon segment with 3 to 20 carbon atoms.

The present invention includes compositions and methods for the treatment, softening and removal of ear wax by administering to the ear a solution of a semi-fluorinated alkane according to the formula: RFRH or RFRHRF, wherein RF is a perfluorinated hydrocarbon segment with 20 or less carbon atoms, and RH is a non-fluorinated hydrocarbon segment with 3 to 20 carbon atoms.

An assembly of throat lozenge and applicator has improved therapeutic properties, further augmented by following a method consisting of a heating procedure using a flavor or efficacy-enhancing liquid. The throat lozenge is molded onto a distal end of an applicator adapted for holding the throat lozenge at a desired location within the mouth. The lozenge containing a plurality of cavities of specific depth and placement on the upper surface or shell of the lozenge, that following a proscribed method are filled with a therapeutic liquid. The combination of all elements of the invention and following the method results in improved perceived efficacy.

Embodiments of the invention are directed to apparatuses and kits for providing palliative care. An exemplary apparatus comprises an elongate hollow shaft having a first and a second end. An absorbent material may be attached to the first end and the first end may be perforated such that the elongate hollow shaft may be filled with one or more liquid solutions that flow through the perforated end and disperse evenly throughout the absorbent material. A kit may additionally be provided for providing customized palliative care. The kit may comprise a means for injecting one or more liquid solutions into the elongate shaft. The kit may additionally comprise apparatuses that are prefilled with one or more liquid solutions.